Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal study
Steatotic Liver Disease and Cancer: Study Targets Critical Gaps in Subgroup Incidence Rates to Guide Public Health Action!
Detailed subgroup incidence rates for steatotic liver disease (SLD)-related hepatocellular carcinoma (HCC) are critical to inform practice and public health interventions but remain sparse. We aimed to fill in this gap.
Steatotic liver disease (SLD) is the most common chronic liver disease with increasing prevalence and incidence globally [1–3]. In recent decades, SLD has also become a major cause of hepatocellular carcinoma (HCC). Additionally, survival rates for patients with SLD-related HCC are less favorable compared to those for patients with viral hepatitis-related HCC, largely attributed to lack of routine HCC surveillance [4,5]. Together, these data highlight the urgency for better risk stratification to estimate accurate HCC incidence rates to assist with prevention, HCC surveillance, and better HCC detection strategies. The new definition of SLD is an inclusive diagnosis rather than an exclusive disease diagnosis, and it provides a well-defined description that avoids misclassification. At the same time, the new nomenclature aims to minimize the stigmatization of patients [6,7].
Click here to access the article.